Joerg Moeller via Getty
Bayer hands over a big drug R&D operation to CRO amid an ongoing restructuring effort
Bayer’s 400-strong small molecule R&D team is being carved out and handed to a CRO, where they’ll continue to work for Bayer.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
